Some of the content on this website requires JavaScript to be enabled in your web browser to function as intended. While the website is still usable without JavaScript, it should be enabled to enjoy the full interactive experience.

Skip to Main Navigation. Each navigation link will open a list of sub navigation links.

Skip to Main Content

Wyoming Drug Utilization Review (WY-DUR)|School of Pharmacy | College of Health Sciences

Contact Us

Wyoming Drug Utilization Review (WY-DUR)
Dept. 3375
1000 E. University Ave.
Laramie, WY 82070
Phone: 307-766-6750
Fax: 307-766-2953


The Draft 2016 PDL is available for review. Please submit comments before January 1, 2016.

New Drug Review: Possible P & T Committee Decisions (May 2015)

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit 

Public Comment at Meetings

 A new policy for public comment at meetings is effective December 1, 2012. 

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the August 13, 2015 P & T Committee meeting.

  • Methylphenidate maximum dosage has been set at 90 mg per day for all types and dosage forms.
  • There was no evidence of a significant difference in safety or efficacy for Rexulti compared to the existing atypical antipsychotics.  It will be limited to those aged 18 and above and a dose of 150% of the labeled maximum (6 mg per day).  A cost analysis will be conducted to determine placement on the Preferred Drug List.
  • Daklinza and Technivie will be allowed for treatment of Hepatitis C within their specific genotype indications and contraindications.  Existing clinical criteria for the class will be applied.
  • Varubi will be limited to patients with a cancer diagnosis.
  • Humira will be approved for the diagnosis of hidradenitis supperativa following trial and failure of other treatment options.

Comments may be sent by email to or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY   82071.   Comments should be received prior to January 1, 2016.

Board Meetings 

Agenda November 12, 2015

Minutes November 12, 2015

2015 Meetings

Wednesday, February 18; Thursday, May 14; Thursday, August 13; Thursday, November 12

All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.

Share This Page:

Footer Navigation

University of Wyoming Medallion
1000 E. University Ave. Laramie, WY 82071 // UW Operators (307) 766-1121 // Contact Us // Download Adobe Reader // Accessibility Accessibility information icon